Mounjaro maintenance dose on the NHS: the reality behind the headlines

The biggest misconception: the NHS maintenance dose is not simply 'prescribed and handed over'

People often read that Mounjaro is available on the NHS and picture walking into a GP surgery, asking for the 15 mg pen, and leaving with a prescription. That's not how it works at any stage of the NHS pathway, and it's especially not how maintenance doses are reached.

Mounjaro's licensed schedule begins at 2.5 mg. That first dose exists to let your body adjust, not to produce immediate weight loss. Titration happens in roughly four-week steps under prescriber supervision, guided by tolerance and response. Reaching the higher maintenance doses (10 mg, 12.5 mg or 15 mg) can take months of incremental increases, and a prescriber must review your progress before each one. If you'd like to understand the clinical picture at the 10 mg point specifically, our page on moving to the 10 mg dose covers what that step typically involves.

On the NHS, this titration happens within the service that prescribes it. Miss a review appointment, change area, or fall outside the service's scope and the chain breaks. The headline ('Mounjaro is now on the NHS') is accurate but incomplete. The reality is a structured, monitored clinical programme with gatekeeping at every step, not a standing prescription you collect at any pharmacy.

Who the NHS actually covers right now, and what's still to come

NHS England's phased rollout is based on NICE's appraisal of tirzepatide (TA1026), published in December 2024 and updated September 2025. The current cohort, active from June 2025, requires a BMI of 40 or above plus four or more of five specific conditions: high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease and type 2 diabetes. If your BMI is from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, the threshold drops by 2.5 kg/m² throughout.

A second cohort opened in June 2026, covering BMI 35–39.9 with four or more conditions. A further expansion to three qualifying conditions is planned for around March 2027. Even within qualifying cohorts, patients must join a structured wraparound support programme (diet, activity and behavioural guidance) as a condition of treatment. Meeting the BMI number does not guarantee access; your local integrated care board determines what's actually commissioned in your area.

If you want a fuller picture of how the NHS rollout works, our NHS Mounjaro guide maps the phases in detail. And if you're looking at providers broadly, this overview of maintenance-dose providers sets out what the private market looks like alongside the NHS route.

Private maintenance doses: what changes, what stays the same

A private prescription does not mean a less rigorous one. At a GPhC-registered pharmacy like nume, a named prescriber (a real clinician, not software) reads your consultation answers the same day. There's photo-ID verification, live weight confirmation on video, GP notification in line with GPhC guidance, and clinical re-review before every repeat order. The titration schedule is the same licensed one: you do not jump to 15 mg on week one because you'd prefer to.

What private treatment removes is the cohort queue. If a prescriber assesses you as clinically suitable for Mounjaro (BMI of 30 or above, or 27 or above with a relevant weight-related condition) you can begin without a referral or a waiting list. One transparent price covers the consultation, prescription, medicine and free next-working-day delivery via DPD in plain packaging. There are no hidden fees and no subscription; every repeat is reviewed before it's sent.

Before the kettle's even boiled, some people have already submitted a consultation and had it reviewed by lunchtime on the same working day. That speed doesn't come at the cost of clinical rigour, it reflects what a well-run private pharmacy can do without the administrative layers an NHS pathway requires. For context on what private treatment costs, our pricing page explains the market honestly.

What the evidence actually says about reaching maintenance

The SURMOUNT-1 trial (published in the New England Journal of Medicine) reported an average body-weight reduction of around 20–21% at the 15 mg dose over 72 weeks, in adults with obesity but without type 2 diabetes. Those results were achieved within the trial's structured programme, which included regular clinical contact. Reaching and sustaining maintenance doses in real-world use depends on the same principle: consistent clinical support through the titration, not just the medicine itself.

If weight loss is less than 5% after six months at the highest tolerated dose, NICE guidance says continuing treatment should be reviewed. That built-in review point applies on both the NHS and private routes, a legitimate prescriber will raise it, not ignore it. Our main Mounjaro guide covers the full evidence picture, including SURMOUNT-5's head-to-head comparison data. For those specifically looking at the highest licensed dose, the 15 mg page explains what reaching that point involves clinically. If you are earlier in your titration journey, our guides on how to get the 3.75 mg dose, moving up to the 5 mg step-up dose, and progressing to 10 mg from 7.5 mg walk through what each of those earlier increases involves.

Check your eligibility through a free consultation with our prescribers at the nume treatment page, no commitment required.